Bizaxofusp

比索芙普

Report date: 2024/10/31 20:00:05

Base Information

Drug NameBizaxofusp
Drug Alias NameInterleukin-4-Pseudomonas exotoxinInterleukin-4 PE38KDEL immunotoxinInterleukin-4 PE38KDEL cytotoxinInterleukin-4-Pseudomonas exotoxin fusion proteinIL-4 Superkines +[10] 
ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunostimulants
TargetsInterleukin-4 receptor subunit alpha
Therapy Area/IndicationsCNS Embryonal TumorKidney NeoplasmsLung Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNeurocrine Biosciences IncNational Institute of Health, Islamabad
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSophiris Bio CorpNational Institute Of Allergy And Infectious Diseases (Niaid)Neurocrine Biosciences Inc +[4] 
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorKidney NeoplasmsLung Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A